Research graph
References from The Impact of KRAS Mutation on Treatment Response and Survival in Patients with Metastatic Lung Adenocarcinoma Receiving First-line Systemic Therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
10.1038/s41572-024-00551-9
10.1038/s41572-024-00551-9 · External reference
Five-year overall survival and prognostic factors in patients with lung cancer: re-sults from the Korean Association of Lung Cancer Registry (KALC-R) 2015
10.4143/crt.2022.264 · 2023 · External reference
Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience
10.1016/j.jtho.2019.01.020 · 2019 · External reference
Developments in predictive biomarker testing and tar-geted therapy in advanced stage non-small cell lung cancer and their application across Eu-ropean countries
10.1016/j.lanepe.2024.100838 · 2024 · External reference
Across the universe of K-RAS mutations in non-small-cell-lung cancer
10.2174/13816128113196660761 · 2014 · External reference
Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications
10.1586/17476348.2016.1115349 · 2016 · External reference
KRAS-mutant non-small cell lung cancer: converging small molecules and immune checkpoint inhibition
10.1016/j.ebiom.2019.02.049 · 2019 · External reference
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and thera-peutic vulnerabilities
10.1158/2159-8290.cd-14-1236 · 2015 · External reference
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
10.18632/oncotarget.5607 · 2015 · External reference
KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer
10.3390/cancers14092063 · 2022 · External reference
Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis and review
10.18632/oncotarget.17594 · 2017 · External reference
Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: a real-world study in a Chinese population
10.3389/fonc.2022.1070761 · 2023 · External reference
The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis
10.1186/s12935-024-03498-9 · 2024 · External reference
Real-world retrospective study of KRAS mutations in ad-vanced non-small cell lung cancer in the era of immunotherapy
10.1002/cncr.34731 · 2023 · External reference
KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunothera-py combined with platinum-based chemotherapy: a retrospective cohort study from China
10.21037/tlcr-22-655 · 2022 · External reference
Clinical outcomes of KRAS-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study
10.21037/tlcr-23-449 · 2023 · External reference
Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: a retrospective analysis
10.1515/med-2023-0653 · 2023 · External reference
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
10.1016/j.canlet.2019.10.027 · 2020 · External reference
Overcoming KRAS-mutant lung cancer
10.1200/edbk_360354 · 2022 · External reference
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immu-notherapy
10.1016/j.ctarc.2023.100767 · 2023 · External reference
STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)
10.1016/j.lungcan.2022.06.010 · 2022 · External reference
A critical review of the prognostic and predictive implications of KRAS and STK11 mutations and co-mutations in metastatic non-small lung cancer
10.3390/jpm13061010 · 2023 · External reference
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
10.1038/s41416-024-02746-z · 2024 · External reference
A real-world experience on the efficacy of first-line treatment with immune-checkpoint inhibitors in non-small-cell lung cancer patients with PD-L1 expression ≥50%: the role of KRAS mutations
10.3390/cancers17243980 · 2025 · External reference
Efficacy of immune checkpoint inhibi-tors in KRAS-mutant non-small cell lung cancer (NSCLC)
10.1016/j.jtho.2019.01.011 · 2019 · External reference
KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: a meta-analysis of 41 studies
10.18632/oncotarget.7080 · 2016 · External reference
